Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8795679 | 0.86 | AR (0.45) | SMN1; SMN2ALDH1A1ARACACB | |
| SCHEMBL12646435 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARAPPARGALDH1A1 | |
| SCHEMBL16242011 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2PPARAPPARGCYP4F2CYP4A11 | |
| SCHEMBL4277047 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARAPPARGALDH1A1 | |
| SCHEMBL10066804 | 0.74 | AR (0.44) | SMN1; SMN2ALDH1A1ARACACB | |
| SCHEMBL5159161 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2PPARAPPARGALDH1A1 | |
| SCHEMBL6112957 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2PPARAPPARGCYP4F2CYP4A11 | |
| SCHEMBL6112960 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2PPARAPPARGCYP4F2CYP4A11 | |
| SCHEMBL12923711 | 0.73 | ACACB (0.44) | ACACB | |
| SCHEMBL11550284 | 0.73 | SMN1; SMN2 (0.67) | SMN1; SMN2PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468737-B1 | SULFONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2468737-A1 | SULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120129891-A1 | SULFONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129891-A1 | SULFONE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | SMN1; SMN2 286/4885PPARA 848/4885PPARG 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.